Unlocking trapped value: Sanofi mulls $30 bn consumer business spinoff

All businesses are undergoing thorough reviews at the moment, according to the Paris-based company.

Want the lowdown on European markets? In your inbox before the open, every day. Sign up here. Sanofi is holding discussions over options for its consumer-health business that could be worth $30 billion as new Chief Executive Officer Paul Hudson seeks to rejuvenate the French drugmaker, people familiar with the matter said. While the pharma giant has made no decisions, it has been talking to financial advisers to gauge shareholder feedback, according to the people, who asked not to be identified because the deliberations are private. Hudson, who has said he will take a critical look at all of Sanofi’s